Commerzbank Aktiengesellschaft FI Raises Stake in Kenvue Inc. $KVUE

Commerzbank Aktiengesellschaft FI boosted its stake in Kenvue Inc. (NYSE:KVUE) by 433.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 78,668 shares of the company’s stock after purchasing an additional 63,909 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Kenvue were worth $1,277,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Kenvue by 1.8% in the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after acquiring an additional 4,101,880 shares during the period. Geode Capital Management LLC increased its holdings in Kenvue by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock worth $1,021,267,000 after acquiring an additional 604,953 shares during the period. Independent Franchise Partners LLP lifted its stake in Kenvue by 233.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after purchasing an additional 21,886,537 shares in the last quarter. American Century Companies Inc. boosted its holdings in Kenvue by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after purchasing an additional 8,436,166 shares during the period. Finally, Norges Bank purchased a new position in shares of Kenvue during the 2nd quarter valued at $537,418,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

NYSE:KVUE opened at $17.82 on Monday. The company has a market capitalization of $34.14 billion, a price-to-earnings ratio of 23.76 and a beta of 0.60. The business has a 50 day moving average of $17.05 and a 200 day moving average of $18.13. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. During the same period last year, the firm posted $0.28 earnings per share. The business’s revenue was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.7%. The ex-dividend date was Wednesday, November 12th. Kenvue’s dividend payout ratio is presently 110.67%.

Insider Activity

In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were purchased at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the acquisition, the director owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on KVUE shares. The Goldman Sachs Group lowered their price objective on Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, October 2nd. Deutsche Bank Aktiengesellschaft set a $18.00 target price on Kenvue in a research note on Friday, October 24th. JPMorgan Chase & Co. dropped their price target on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Canaccord Genuity Group reissued a “hold” rating and set a $15.00 price objective (down previously from $26.00) on shares of Kenvue in a report on Wednesday, October 29th. Finally, Evercore ISI set a $18.00 target price on shares of Kenvue in a research note on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $20.23.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.